To evaluate the utility of TRAIL as a cancer therapeutic, human TRAIL (Dulanermin/AMG 951/RG3639) was created (Table 2), which induces cell death in glioma, melanoma, Kaposi’s sarcoma, and breast cancer [65,66,67]. Here, TNFSF10 is linked to central nervous system cancer.